<DOC>
	<DOCNO>NCT01651403</DOCNO>
	<brief_summary>This placebo-controlled study evaluate efficacy , safety tolerability tenofovir disoproxil fumarate ( TDF ) participants 2 &lt; 12 year old chronic Hepatitis B infection . While study show significant virologic response adult adolescent , effect child well establish . This study provide valuable data help establish efficacy safety profile TDF child . The study consist 48 week blind randomized treatment , participant switch open-label TDF treatment additional 144 week .</brief_summary>
	<brief_title>Evaluating Efficacy , Safety Tolerability Tenofovir DF Pediatric Patients With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Male Female , 2 &lt; 12 year age Weight ≥ 10kg Chronic HBV infection ≥ 6 month HBeAgpositive HBeAgnegative HBV Viral Load ≥ 100,000 copies/mL Alanin aminotransferase ( ALT ) ≥ 1.5 x upper limit normal range ( ULN ) screen Creatinine Clearance ≥ 80 mL/min Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 , hemoglobin ≥ 10g/dL Negative pregnancy test screening No prior tenofovir DF therapy ( subject may receive prior interferon‑alfa and/or oral anti‑HBV nucleoside/nucleotide therapy ; subject must discontinue interferonalfa therapy ≥ 6 month prior screen ; subject experience antiHBV nucleoside/nucleotide therapy must discontinue therapy ≥ 16 week prior screen avoid flare randomize placebo arm ) Key Pregnant lactate Decompensated liver disease Received interferon therapy within 6 month Screening Received antiHBV nucleoside/nucleotide therapy within 16 week Screening Alphafetoprotein level &gt; 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) Coinfection HIV , acute hepatitis A virus ( HAV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) Chronic liver disease due HBV History significant renal , cardiovascular , pulmonary , neurological bone disease Long term nonsteroidal , antiinflammatory drug therapy Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
</DOC>